Teriflunomide for the treatment of relapsing-remitting multiple sclerosis

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Teriflunomide, a once-daily, oral disease-modifying therapy, is a valuable new treatment option for the management of patients with relapsing-remitting multiple sclerosis. This article reviews key efficacy and safety data arising from pivotal teriflunomide studies that demonstrate the utility in treating both treatment-naïve patients and those previously treated with another disease-modifying therapy who, for a variety of reasons, may require an alternative treatment.

Original languageEnglish
Pages (from-to)181-194
Number of pages14
JournalExpert Review of Clinical Immunology
Issue number2
StatePublished - 1 Feb 2015


  • clinical trials
  • disability
  • multiple sclerosis
  • progression
  • relapsing-remitting
  • teriflunomide


Dive into the research topics of 'Teriflunomide for the treatment of relapsing-remitting multiple sclerosis'. Together they form a unique fingerprint.

Cite this